182 related articles for article (PubMed ID: 35254481)
21.
Wondergem M; van der Zant FM; Broos WAM; Roeleveld TA; Donker R; Ten Oever D; Geenen RWF; Knol RJJ
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):521-531. PubMed ID: 32719916
[TBL] [Abstract][Full Text] [Related]
22. A Pilot Study of Dynamic
Lu M; Lindenberg L; Mena E; Turkbey B; Seidel J; Ton A; McKinney Y; Eclarinal P; Merino M; Pinto P; Choyke P; Adler S
Mol Imaging Biol; 2022 Jun; 24(3):444-452. PubMed ID: 34724140
[TBL] [Abstract][Full Text] [Related]
23. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):546-555. PubMed ID: 31730876
[TBL] [Abstract][Full Text] [Related]
24. Repeatability of Quantitative
Jansen BHE; Cysouw MCF; Vis AN; van Moorselaar RJA; Voortman J; Bodar YJL; Schober PR; Hendrikse NH; Hoekstra OS; Boellaard R; Oprea-Lager DE
J Nucl Med; 2020 Sep; 61(9):1320-1325. PubMed ID: 31924729
[TBL] [Abstract][Full Text] [Related]
25. Role of
Zhang T; Yang S; Lin L; Wang S; Xia D; Chen D; Wang G; Zhao K; Su X
Hell J Nucl Med; 2022; 25(1):11-18. PubMed ID: 35388799
[TBL] [Abstract][Full Text] [Related]
26. Low levels of PSMA expression limit the utility of
Campbell SP; Baras AS; Ball MW; Kates M; Hahn NM; Bivalacqua TJ; Johnson MH; Pomper MG; Allaf ME; Rowe SP; Gorin MA
Ann Nucl Med; 2018 Jan; 32(1):69-74. PubMed ID: 29067547
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients.
Liu Y; Wang G; Yu H; Wu Y; Lin M; Gao J; Xu B
Nucl Med Commun; 2020 Dec; 41(12):1299-1305. PubMed ID: 32941403
[TBL] [Abstract][Full Text] [Related]
28.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
29. Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it.
Rowe SP; Voter AF; Werner RA; Zukotynski KA; Pomper MG; Gorin MA; Solnes LB
Can J Urol; 2023 Feb; 30(1):11432-11437. PubMed ID: 36779950
[TBL] [Abstract][Full Text] [Related]
30. Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT.
McLaughlin LA; Yildirim O; Rosenblum MK; Imber BS; Haseltine JM; Zelefsky MJ; Schöder H; Morris MJ; Rafelson WM; Krebs S; Moss NS
J Neurooncol; 2023 Jun; 163(2):455-462. PubMed ID: 37247180
[TBL] [Abstract][Full Text] [Related]
31. Matched-Pair Comparison of
Wondergem M; van der Zant FM; Broos WAM; Knol RJJ
J Nucl Med; 2021 Oct; 62(10):1422-1429. PubMed ID: 33547211
[TBL] [Abstract][Full Text] [Related]
32. Prospective Evaluation of
Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
[No Abstract] [Full Text] [Related]
33. Intra-individual comparison of
Ferreira G; Iravani A; Hofman MS; Hicks RJ
Cancer Imaging; 2019 May; 19(1):23. PubMed ID: 31092293
[TBL] [Abstract][Full Text] [Related]
34. Combination of MRI prostate and 18F-DCFPyl PSMA PET/CT detects all clinically significant prostate cancers in treatment-naive patients: An international multicentre retrospective study.
Parathithasan N; Perry E; Taubman K; Hegarty J; Talwar A; Wong LM; Sutherland T
J Med Imaging Radiat Oncol; 2022 Oct; 66(7):927-935. PubMed ID: 35170858
[TBL] [Abstract][Full Text] [Related]
35. Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
Yin Y; Werner RA; Higuchi T; Lapa C; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
J Nucl Med; 2019 Apr; 60(4):511-516. PubMed ID: 30190303
[TBL] [Abstract][Full Text] [Related]
36. Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
Meijer D; Jansen BHE; Wondergem M; Bodar YJL; Srbljin S; Vellekoop AE; Keizer B; van der Zant FM; Hoekstra OS; Nieuwenhuijzen JA; Dahele M; Vis AN; Oprea-Lager DE
PLoS One; 2020; 15(10):e0239414. PubMed ID: 33021980
[TBL] [Abstract][Full Text] [Related]
37. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
Werner RA; Bundschuh RA; Bundschuh L; Lapa C; Yin Y; Javadi MS; Buck AK; Higuchi T; Pienta KJ; Pomper MG; Lodge MA; Gorin MA; Rowe SP
Mol Imaging Biol; 2020 Feb; 22(1):190-197. PubMed ID: 31140110
[TBL] [Abstract][Full Text] [Related]
38. Piflufolastat F-18 (
Voter AF; Werner RA; Pienta KJ; Gorin MA; Pomper MG; Solnes LB; Rowe SP
Expert Rev Anticancer Ther; 2022 Jul; 22(7):681-694. PubMed ID: 35603510
[TBL] [Abstract][Full Text] [Related]
39. A Multicenter Prospective Clinical Trial of
McCarthy M; Francis R; Tang C; Watts J; Campbell A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
[TBL] [Abstract][Full Text] [Related]
40. A Comparison of
Fourquet A; Rosenberg A; Mena E; Shih JJ; Turkbey B; Blain M; Bergvall E; Lin F; Adler S; Lim I; Madan RA; Karzai F; Gulley JL; Dahut WL; Wood BJ; Chang R; Levy E; Choyke PL; Lindenberg L
J Nucl Med; 2022 May; 63(5):735-741. PubMed ID: 34475237
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
